Pantoprazol Accord (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Accord, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Accord is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.

Adverse reactions to Pantoprazol Accord may range from mild to severe.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: signs of hepatic stress in blood tests. - Fracture risk: potential decrease in bone mineral density with long‑term use.

When prescribing Pantoprazol Accord, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term therapy: evaluate need for periodic reassessment of bone health. - Pregnancy and lactation: use only if clearly needed after risk‑benefit analysis. - Elderly patients: start with the lowest effective dose and monitor for adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Accord can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Methotrexate: reduced renal clearance may raise systemic exposure. - Digoxin: altered absorption may change serum levels. - Clopidogrel: potential reduction in antiplatelet effect. - Iron supplements: decreased iron absorption, consider timing separation.